These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2787650)

  • 21. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
    Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
    Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
    [No Abstract]   [Full Text] [Related]  

  • 22. Tumor-specific immunotherapy by active immunization with haptenic muramyl dipeptide derivative-coupled tumor cells.
    Fujiwara H; Shima J; Sano H; Kosugi A; Nakajima H; Hamaoka T
    Prog Clin Biol Res; 1987; 244():335-44. PubMed ID: 2958872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.
    Toes RE; Offringa R; Feltkamp MC; Visseren MJ; Schoenberger SP; Melief CJ; Kast WM
    Behring Inst Mitt; 1994 Jul; (94):72-86. PubMed ID: 7998917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects on tumor growth in vivo by manipulation of the tumor immune response.
    Sjögren HO
    Johns Hopkins Med J Suppl; 1974; 3():51-60. PubMed ID: 4370816
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunotherapy of murine sarcomas with auto-anti-idiotypic monoclonal antibodies which bind to tumor-specific T cells.
    Nelson KA; George E; Swenson C; Forstrom JW; Hellström KE
    J Immunol; 1987 Sep; 139(6):2110-7. PubMed ID: 2957449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does antibody-dependent epitope masking permit progressive tumour growth in the face of cell-mediated cytotoxicity?
    Manson LA
    Immunol Today; 1991 Oct; 12(10):352-5. PubMed ID: 1720318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunological analysis of melanoma-specific antigen].
    Wakabayashi S; Okamoto S
    Nihon Hifuka Gakkai Zasshi; 1985 Oct; 95(11):1145-51. PubMed ID: 3879298
    [No Abstract]   [Full Text] [Related]  

  • 30. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?
    Campoli M; Ferrone S
    Expert Rev Vaccines; 2004 Apr; 3(2):171-87. PubMed ID: 15056043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.
    Ellenhorn JD; Schreiber H; Bluestone JA
    J Immunol; 1990 Apr; 144(7):2840-6. PubMed ID: 1969454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.
    Nair SK; Heiser A; Boczkowski D; Majumdar A; Naoe M; Lebkowski JS; Vieweg J; Gilboa E
    Nat Med; 2000 Sep; 6(9):1011-7. PubMed ID: 10973321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Requirements for T cell recognition and elimination of retrovirally-transformed cells.
    Greenberg P; Klarnet J; Kern D; Okuno K; Riddell S; Cheever M
    Princess Takamatsu Symp; 1988; 19():287-301. PubMed ID: 2479634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Harnessing T-lymphocytes for human cancer immunotherapy.
    Hirshaut Y; Slovin SF
    Cancer; 1985 Sep; 56(6):1366-73. PubMed ID: 3896456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular and humoral immune responses of cancer patients to defined tumor antigens.
    Jäger D; Jäger E; Bert F; Knuth A
    Cancer Chemother Biol Response Modif; 2001; 19():385-93. PubMed ID: 11686025
    [No Abstract]   [Full Text] [Related]  

  • 36. Peptide mimics of a tumor antigen induce functional cytotoxic T cells.
    Apostolopoulos V; Lofthouse SA; Popovski V; Chelvanayagam G; Sandrin MS; McKenzie IF
    Nat Biotechnol; 1998 Mar; 16(3):276-80. PubMed ID: 9528009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells.
    Riemer AB; Hantusch B; Sponer B; Kraml G; Hafner C; Zielinski CC; Scheiner O; Pehamberger H; Jensen-Jarolim E
    Cancer Immunol Immunother; 2005 Jul; 54(7):677-84. PubMed ID: 15565329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cell suppression as an obstacle to immunologically-mediated tumor regression: elimination of suppression results in regression.
    North RJ; Awwad M
    Prog Clin Biol Res; 1987; 244():345-58. PubMed ID: 2958873
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunological response in the mouse brain: II. Experimental immunotherapy model against transplanted mouse lymphoma in the brain.
    Keyaki A; Handa H; Yamashita J; Kuribayashi K; Masuda T
    Nihon Geka Hokan; 1988 May; 57(3):202-14. PubMed ID: 3266837
    [No Abstract]   [Full Text] [Related]  

  • 40. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory.
    Dai J; Liu B; Caudill MM; Zheng H; Qiao Y; Podack ER; Li Z
    Cancer Immun; 2003 Jan; 3():1. PubMed ID: 12747743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.